Adaptin Bio (APTN) Cash from Financing Activities (2023 - 2026)

Adaptin Bio (APTN) has 4 years of Cash from Financing Activities data on file, last reported at $438433.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 90.51% year-over-year to $438433.0; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (down 80.39% YoY), and the FY2025 full-year result was $5.2 million, up 666.71% from the prior year.
• Cash from Financing Activities declined to $438433.0 in Q1 2026, from $582961.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $4.6 million in Q1 2025 to a low of -$193876.0 in Q4 2024.
• A 4-year average of $797296.9 and a median of $330487.5 in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities plunged 432.28% in 2024 and soared 5033.36% in 2025, its largest moves.
• Tracing APTN's Cash from Financing Activities over 4 years: stood at $58347.0 in 2023, then sank by 432.28% to -$193876.0 in 2024, then soared by 400.69% to $582961.0 in 2025, then declined by 24.79% to $438433.0 in 2026.
• Business Quant data shows APTN's Cash from Financing Activities at $438433.0 in Q1 2026, $582961.0 in Q4 2025, and $4.6 million in Q1 2025.